Skip to main content
. 2024 May 28;111(1):102–106. doi: 10.4269/ajtmh.23-0549

Figure 1.

Figure 1.

Proportion of participants with IgG-positive serum in (A) baseline 50% microneutralization assay (MNT50)–seropositive and (B) baseline MNT50–seronegative participants by vaccine dose group at baseline and days 15 and 30 (per-protocol set). The percentage of IgG-positive participants and 95% CI are shown. HD-TDV = high-dose formulation; TDV = approved formulation.